Daptomycin: a novel agent for Gram-positive infections
The DOI matches its Crossref record.
Abstract
The alarming increase in the incidence of Gram-positive infections, including those caused by resistant bacteria, has sparked renewed interest in novel antibiotics. One such agent is daptomycin, a novel lipopeptide antibiotic with proven bactericidal activity in vitro against all clinically relevant Gram-positive bacteria. These include resistant pathogens, such as vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide intermediately susceptible Staphylococcus aureus (GISA), coagulase-negative staphylococci (CNS) and penicillin-resistant Streptococcus pneumoniae (PRSP), for which there are very few therapeutic alternatives. Daptomycin provides rapid, concentration-dependent killing and a relatively prolonged concentration-dependent post-antibiotic effect in vitro. Spontaneous acquisition of resistance to daptomycin occurs rarely. Daptomycin exhibits linear pharmacokinetics, minimal accumulation with once-daily dosing, and low plasma clearance and volume of distribution. Phase II clinical trials indicate that daptomycin at doses of 2 mg/kg q24 h and 3 mg/kg q12 h is efficacious against skin and soft tissue infections and bacteremia, respectively. In addition, results in endocarditis suggested potential efficacy with higher doses. On the basis of clinical trials to date, it appears that daptomycin has an excellent safety profile, with the incidence and nature of serious adverse events comparable to those observed with conventional therapy. Adverse events associated with other classes of antimicrobials (nephrotoxicity, local irritation, ototoxicity, hypersensitivity, and gastrointestinal effects) were uncommon with daptomycin. Minimal skeletal muscle toxicity was seen at only the highest dose tested (4 mg/kg q12 h), predicted by elevations in serum creatinine phosphokinase, and readily reversible upon discontinuation of treatment. There were no signs of toxicity in cardiac or smooth muscle. Phase II and III clinical trials are underway to evaluate daptomycin for the treatment of Gram-positive bacteremia and complicated skin and soft tissue infections, respectively. Daptomycin holds promise as a rapidly acting and highly effective antibiotic for Gram-positive infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Biosurfactants: Multifunctional Biomolecules of the 21st Century
Santos, D., Rufino, R., Luna, J., Santos, V., & Sarubbo, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030401 · Cited by 1,073
Arbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., & Daptomycin 98-01 and 99-01 Investigators (2004) · Clinical Infectious Diseases · doi:10.1086/420818 · Cited by 689
Self-citationJi, H., Li, X., & Zhang, H. (2009) · EMBO reports · doi:10.1038/embor.2009.12 · Cited by 636
Cui, L., Tominaga, E., Neoh, H.-M., & Hiramatsu, K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.1079-1082.2006 · Cited by 427
Natural products to drugs: daptomycin and related lipopeptide antibiotics
Baltz, R. H., Miao, V., & Wrigley, S. K. (2005) · Natural Product Reports · doi:10.1039/b416648p · Cited by 393
Miao, V., Coëffet-LeGal, M.-F., Brian, P., Brost, R., Penn, J., Whiting, A., Martin, S., Ford, R., Parr, I., Bouchard, M., et al. (2005) · Microbiology · doi:10.1099/mic.0.27757-0 · Cited by 368
Carpenter, C. F., & Chambers, H. F. (2004) · Clinical Infectious Diseases · doi:10.1086/383472 · Cited by 358
Dvorchik, B. H., Brazier, D., DeBruin, M. F., & Arbeit, R. D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1318-1323.2003 · Cited by 358
Development of daptomycin for Gram-positive infections
Tally, F. P., & DeBruin, M. F. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.4.523 · Cited by 321
Self-citationCommunity-acquired methicillin-resistant Staphylococcus aureus
Elston, D. M. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.04.018 · Cited by 308
Structural Transitions as Determinants of the Action of the Calcium-Dependent Antibiotic Daptomycin
Jung, D., Rozek, A., Okon, M., & Hancock, R. E. W. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.04.020 · Cited by 297
Bhavnani, S. M., Rubino, C. M., Ambrose, P. G., & Drusano, G. L. (2010) · Clinical Infectious Diseases · doi:10.1086/652767 · Cited by 280
Self-citationSakoulas, G., Alder, J., Thauvin-Eliopoulos, C., Moellering, R. C., & Eliopoulos, G. M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1581-1585.2006 · Cited by 262
Pharmacodynamics of Daptomycin in a Murine Thigh Model of Staphylococcus aureus Infection
Louie, A., Kaw, P., Liu, W., Jumbe, N., Miller, M. H., & Drusano, G. L. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.845-851.2001 · Cited by 172
“In previous studies, daptomycin compared favorably with vancomycin in the treatment of soft tissue and skin infections ( 31 ).”
BackgroundResultInfluentialSelf-citationGrégoire, N., Marchand, S., Ferrandière, M., Lasocki, S., Seguin, P., Vourc’h, M., Barbaz, M., Gaillard, T., Launey, Y., Asehnoune, K., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky374 · Cited by 38
Metadata
- Authors
- Tally, F. P., Zeckel, M., Wasilewski, M. M., Carini, C., Berman, C. L., Drusano, G. L., & Oleson JR, F. B.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 1999-08
- Volume
- 8
- Issue
- 8
- Pages
- 1223-1238
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2065724789
- Cited by
- 205
- References
- 0
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.